• Publications
  • Influence
Improved survival with ipilimumab in patients with metastatic melanoma.
TLDR
Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Expand
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
TLDR
Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dACarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma. Expand
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
TLDR
The data show that exosome production, transfer and education of bone marrow cells supports tumor growth and metastasis, has prognostic value and offers promise for new therapeutic directions in the metastatic process. Expand
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
TLDR
Systematic criteria, designated immune-related response criteria, were defined in an attempt to capture additional response patterns observed with immune therapy in advanced melanoma beyond those described by Response Evaluation Criteria in Solid Tumors or WHO criteria. Expand
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
TLDR
Treatment efficacy was associated with a higher number of mutations in the tumors, and a tumor-specific T cell response paralleled tumor regression in one patient, suggesting that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy. Expand
Nivolumab plus ipilimumab in advanced melanoma.
TLDR
Conurrent therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients. Expand
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
TLDR
In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. Expand
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
TLDR
Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipILimumab alone, and in patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone. Expand
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
TLDR
These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti-CTLA- 4 agents are being considered. Expand
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
TLDR
The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipILimumab monotherapy. Expand
...
1
2
3
4
5
...